If you searched GLP-3 retatrutide, you probably saw the term online or in the news and want to know what it means. Here is the short answer: there is no GLP-3 receptor and no official drug class called GLP-3. Retatrutide is a triple hormone receptor agonist that targets three pathways at once, which is where the nickname came from.
This explainer corrects the taxonomy first, then walks through the three receptors retatrutide actually targets, where it fits among obesity medications, and why the naming distinction matters for anyone reading about this drug. For the deep molecular breakdown of each pathway, see our deep-dive on the triple-agonist mechanism.
Key Takeaways
- "GLP-3" is a nickname, not a real receptor or drug class. No GLP-3 receptor exists in human pharmacology.
- Retatrutide is a triple agonist. It targets the GLP-1, GIP, and glucagon receptors, and the "3" in the nickname counts those three targets.
- Eli Lilly and peer-reviewed journals never say "GLP-3." They call it a triple hormone receptor agonist (molecule ID LY3437943).
- Phase 2 results were strong: up to 24.2% average body weight loss at 48 weeks on the 12mg dose.
- It is investigational. Retatrutide is in Phase 3 trials and is not FDA-approved. Products sold online as "GLP-3 peptide" are not the same compound.
Investigational Status
Retatrutide is not FDA-approved. It is an investigational triple agonist in Phase 3 clinical trials (the TRIUMPH program) developed by Eli Lilly. No commercially available version exists. For trial information, visit ClinicalTrials.gov.
What Is "GLP-3" and Does It Actually Exist?
"GLP-3" is not an official receptor, drug class, or pharmacological term. It is an informal nickname that spread online and in media coverage because retatrutide targets three metabolic pathways. The "3" simply counts those targets. It does not refer to a hormone called GLP-3.
GLP stands for glucagon-like peptide. GLP-1 is a real hormone with a real receptor, and GLP-1 receptor agonists like semaglutide built the entire category. There is also a GLP-2, which acts on the intestinal lining and has nothing to do with metabolism or weight loss. There is no GLP-3 hormone and no GLP-3 receptor. When you see "GLP-3 drug," it is shorthand for a drug that activates three receptor types, not a drug that targets a GLP-3 receptor.
The three receptors retatrutide actually targets are the GLP-1 receptor (GLP-1R), the GIP receptor (GIPR), and the glucagon receptor (GcgR). All three were confirmed in the discovery work published by Coskun and colleagues in Cell Metabolism in 2022. Eli Lilly, which develops the drug, and the peer-reviewed literature consistently describe retatrutide as a triple agonist or triple hormone receptor agonist. The official regulatory framing is an investigational triple agonist.
Quick answer for the search box: "GLP-3" is an informal nickname for retatrutide, a triple hormone receptor agonist that activates the GLP-1, GIP, and glucagon receptors. No GLP-3 receptor exists. The name reflects the number of targets, not a specific hormone class.
Why the Media Started Using "GLP-3"
The linguistic logic is easy to follow. Semaglutide became known as "the GLP-1 drug" because it targets one receptor. Tirzepatide added a second receptor and became "the dual agonist." When retatrutide added a third receptor, shorthand emerged that counted the targets: one, two, three. The result was "GLP-3," a tidy label that stuck even though it is not scientifically precise.
Mainstream outlets reinforced it. Even credible publications have used "GLP-3" as a headline term, which is why the confusion persists. The label is memorable and easy to say. It just is not accurate on the science.
Why This Site Uses "GLP-3" in Its Name
GLP3Planner is named around this search term on purpose, because it is what people type. The site serves people tracking retatrutide (the triple agonist), tirzepatide (the dual agonist), and semaglutide (the GLP-1 agonist). The name meets users where they are while the tools and articles keep the pharmacology accurate. This explainer is part of that mission: validate the question, correct the term, and explain the real mechanism without the marketing gloss.
What Retatrutide Actually Is: The Official Classification
Retatrutide carries the molecule ID LY3437943 and is developed by Eli Lilly. It is investigational, currently in Phase 3 trials, and not approved by any regulator. Its official class is triple hormone receptor agonist, which is the precise way to say it activates three receptors with one molecule.
Practically, it is a subcutaneous injection given once weekly. Trial dosing starts at 2mg and steps up through 4mg and 8mg to a 12mg maximum (2mg → 4mg → 8mg → 12mg), generally every four weeks. Retatrutide has a half-life of approximately 6 days, so it takes roughly four to five weeks to reach steady-state levels at each dose. One drug, three receptor targets: GLP-1R, GIPR, and GcgR.
The Three Receptors Retatrutide Targets
Here is a plain-language summary of each pathway. For the full molecular walkthrough, including signaling detail and per-receptor trial data, read How Does Retatrutide Work?
GLP-1 receptor
Reduces appetite and slows gastric emptying so you feel full longer. This is the same target semaglutide (Ozempic and Wegovy) hits, and it is the foundation of the whole category.
GIP receptor
Improves the body's insulin response and appears to enhance the GLP-1 effect. This is the second receptor that tirzepatide (Mounjaro and Zepbound) targets, which is why tirzepatide is the approved dual agonist. For more on that pairing, see how the approved dual agonist works.
Glucagon receptor
The unique addition in retatrutide. It increases energy expenditure and promotes fat breakdown. No currently approved obesity drug activates this receptor, which is the main reason retatrutide is studied separately from the dual agonists.
Model Your Retatrutide Schedule
Track your retatrutide dosing schedule with GLP3Planner's free pharmacokinetic calculator and see when levels reach steady state.
The Three Generations of Obesity Drug and Where GLP-3 Retatrutide Fits
The cleanest way to understand "GLP-3" is as a generation label, not a receptor class. Obesity medications have moved through three waves, adding a receptor target with each step. The "3" people attach to retatrutide really counts this third generation.
| Generation | Drug class | Example | Receptors | Trial weight loss |
|---|---|---|---|---|
| 1st (monoagonist) | GLP-1 receptor agonist | Semaglutide (Ozempic/Wegovy) | GLP-1R | 14.9% at 68 weeks |
| 2nd (dual agonist) | GLP-1 + GIP agonist | Tirzepatide (Mounjaro/Zepbound) | GLP-1R + GIPR | 20.9% at 72 weeks |
| 3rd (triple agonist) | GLP-1 + GIP + glucagon agonist | Retatrutide (investigational) | GLP-1R + GIPR + GcgR | 24.2% at 48 weeks |
Read this table carefully. Direct cross-trial comparisons are not valid. These trials had different designs, populations, durations, and endpoints. The figures illustrate the trajectory of drug development, not a head-to-head result. No trial has pitted these three drugs against each other in the same study.
That trajectory is what "GLP-3 retatrutide" really refers to: a third generation that stacks a third receptor onto the proven GLP-1 and GIP combination. For a side-by-side comparison of GLP-1 mono, dual, and triple agonist generations, see our GLP-3 vs GLP-1 comparison chart.
Why It Matters That There Is No "GLP-3 Receptor"
This is not pedantry. The confusion has real consequences for anyone trying to research, buy, or evaluate sources about this drug.
Counterfeit labeling risk. Products sold online as "GLP-3 peptide" or "GLP-3 RT" lean on the misnomer. Real retatrutide (LY3437943) is not commercially available. Any product labeled "GLP-3" for sale is using informal terminology and is not Lilly's investigational compound.
Regulatory clarity. Any FDA filing, label, or prescribing document will describe retatrutide as a GLP-1, GIP, and glucagon receptor triple agonist, never as "GLP-3." Knowing this helps you spot which communications are official and which are marketing.
Scientific accuracy. Searching clinical databases for "GLP-3" returns little of value. The useful search terms are the molecule ID LY3437943, the trial program name TRIUMPH, or a combination of GLP-1 and glucagon receptor agonist. The label that spread online is not the label the science uses.
There is no FDA-approved drug called "GLP-3." Retatrutide remains investigational. Products marketed as "GLP-3 peptide" online are not the same as retatrutide and have not been evaluated for safety or efficacy.
The video below, from a licensed physician, walks through why retatrutide's triple-agonist mechanism is different from earlier GLP-1 drugs. It is a useful companion to the naming distinction this article covers.
Retatrutide's Phase 2 Clinical Results
The mechanism is one thing, but the human data is what matters. The clearest evidence comes from the Phase 2 trial published by Jastreboff and colleagues in the New England Journal of Medicine in 2023.
- Design: Phase 2 trial with 338 participants over 48 weeks across multiple dose arms.
- Top result: 24.2% average body weight loss at 48 weeks on the 12mg dose. In context, this is among the highest weight loss figures recorded for an obesity medication in clinical trials.
- Titration: the standard ladder runs 2mg, then 4mg, then 8mg, then 12mg, with about four weeks between steps.
- Tolerability: gastrointestinal effects such as nausea, diarrhea, constipation, and vomiting were the most common, with rates around 50 to 60 percent at the highest dose, mostly mild to moderate and dose-dependent.
Eli Lilly has announced promising Phase 3 data from its TRIUMPH program, and peer-reviewed results are anticipated. Because those figures are not yet in a published, verifiable journal table, this article stays on the confirmed Phase 2 number. For the latest, follow the TRIUMPH trial updates.
For broader context only, semaglutide's STEP 1 trial reported 14.9% average loss at 68 weeks and tirzepatide's SURMOUNT-1 reported 20.9% at 72 weeks. Again, these were different trials with different designs and durations, so treat them as a development timeline rather than a ranking. For the full results breakdown by dose, see what Phase 2 clinical results show at each dose, and for tolerability detail see the side effects of retatrutide in clinical trials.
Is "GLP-3 Retatrutide" the Future of Weight Loss?
The Phase 3 TRIUMPH program is ongoing as of 2026. If those trials succeed, FDA approval is broadly anticipated in the 2027 to 2028 window based on typical trial timelines. Retatrutide is an Eli Lilly drug, not a compounded or generic product, so its path to market runs through the standard regulatory process.
Until then, the only legitimate way to access retatrutide is through an authorized clinical trial. It is not available by prescription, and the products circulating in unregulated online markets are not the same compound. The triple-agonist approach is promising, but "promising in trials" and "approved and available" are two different things. Most of the confusion around "GLP-3 retatrutide" sits in that gap.
If you want to understand how the drug behaves over a dosing schedule before any of that, you can model it now. How retatrutide compares to the approved dual agonist is covered in our retatrutide vs tirzepatide guide.
What to Know Before You Search "GLP-3 Retatrutide" Online
The search results for this term are a mix of legitimate science and grey-market sellers. A few things are worth keeping straight before you click through.
- Products marketed as "GLP-3" online are not FDA-regulated and are not the same compound as Eli Lilly's retatrutide.
- The only legitimate access pathway is enrollment in an authorized clinical trial, which you can look up on public trial registries.
- The proliferation of counterfeit "GLP-3" products is an active regulatory concern, and quality across unregulated sources is inconsistent.
Bottom line: "GLP-3" is a nickname worth understanding, not a product to chase. The accurate term is triple agonist, the drug is retatrutide, and it is investigational.
Frequently Asked Questions
Is retatrutide the same as GLP-3?
"GLP-3" is an informal nickname, not an official drug class. Retatrutide is classified as a triple hormone receptor agonist targeting three receptors: GLP-1R, GIPR, and the glucagon receptor. There is no pharmacological GLP-3 receptor. The nickname spread because retatrutide hits three pathways, and the "3" became shorthand.
Why do people call retatrutide GLP-3?
The label emerged because earlier drugs targeted one receptor (GLP-1) and then two (tirzepatide, the dual agonist). When retatrutide added a third receptor, informal shorthand counted the targets and produced "GLP-3." Media outlets used it as a headline term, which made it mainstream even though it is not pharmacologically accurate.
Is there a real GLP-3 receptor?
No. In human pharmacology, GLP-1 and GLP-2 are the two known glucagon-like peptides, each with its own receptor. There is no GLP-3 receptor. When people say "GLP-3 drug," they mean a drug that targets three receptor types (GLP-1R, GIPR, and the glucagon receptor), not a drug targeting a GLP-3 receptor.
Does GLP-3 retatrutide help with weight loss?
In a Phase 2 trial of 338 participants over 48 weeks, retatrutide at the 12mg dose produced 24.2% average body weight reduction, among the highest figures recorded for an obesity medication in clinical trials. Phase 3 trials under the TRIUMPH program are ongoing as of 2026. Retatrutide is not yet FDA-approved.
What three hormones does retatrutide mimic?
Retatrutide acts on three receptors: GLP-1, which reduces appetite and slows digestion; GIP, which improves insulin response; and glucagon, which increases energy expenditure and promotes fat breakdown. The glucagon component is unique, since no currently approved obesity drug activates it.
How fast does retatrutide work?
Appetite suppression typically becomes noticeable in the first one to two weeks. Because retatrutide has a half-life of about 6 days, steady-state blood levels are reached at roughly four to five weeks. Meaningful weight loss in trials generally built over the following weeks and continued through the 48-week study period at higher doses.
What is the difference between GLP-3 and GLP-1?
"GLP-3" is the informal term for retatrutide, which adds two receptor targets beyond GLP-1: the GIP receptor and the glucagon receptor. GLP-1 drugs like semaglutide target only the GLP-1 receptor. The additional targets in retatrutide are believed to contribute to its higher observed weight loss in trials.
Is GLP-3 retatrutide FDA-approved?
No. Retatrutide, the drug informally called "GLP-3," is investigational and not FDA-approved as of mid-2026. It is in Phase 3 clinical trials under Eli Lilly's TRIUMPH program. No commercial prescriptions are available, and the only legitimate access pathway is an authorized clinical trial.
Where can you buy GLP-3 retatrutide?
Retatrutide cannot be legally purchased. It is an investigational drug available only through authorized clinical trials. Products sold online as "GLP-3 peptide" or "GLP-3 retatrutide" are unregulated and not the same compound. The only legitimate route is enrollment in a TRIUMPH program trial.
Plan Ahead with the Retatrutide Calculator
Visualize how retatrutide builds in your system across a weekly schedule and when it reaches steady state, free.
References
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. [NEJM]
- Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247.e9. [PubMed]
- Katsi V, et al. Retatrutide, A Game Changer in Obesity Pharmacotherapy. PMC. 2025. [PMC]
- Abouelmagd AA, et al. Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist. PMC. 2025. [PMC]
- Eli Lilly and Company. What to know about retatrutide. Lilly.com. [Lilly]
- ClinicalTrials.gov. Retatrutide (LY3437943) TRIUMPH program studies. [ClinicalTrials.gov]
Medical Disclaimer
This article is for informational and educational purposes only and does not constitute medical advice. Retatrutide is an investigational medication not yet approved by the FDA. Do not start, stop, or modify any medication regimen without consulting a qualified healthcare provider. Individual results may vary. Always discuss treatment options, risks, benefits, and alternatives with your doctor.
Related Retatrutide Articles
How Does Retatrutide Work?
The full molecular breakdown of the triple-agonist mechanism.
GLP-3 vs GLP-1 Chart
Single, dual, and triple agonist generations side by side.
Retatrutide Results
What Phase 2 clinical results show at each dose.
vs Tirzepatide
How retatrutide compares to the approved dual agonist.